LABORATORY RESEARCH The Chemokine Receptor CCR7 Promotes Mammary Tumorigenesis through Amplification of Stem-Like Cells CCR7 was found to exert its function by regulating mammary cancer stem-like cells in both murine and human tumors. In vivo experiments showed that loss of CCR7 activity either through deletion or pharmacological antagonism significantly decreased functional pools of stem-like cells in mouse primary mammary tumors, providing a mechanistic explanation for the tumor-promoting role of this chemokine receptor. [Oncogene] Abstract Regulation of Anti-Apoptotic Signaling by Kruppel-Like Factors 4 and 5 Mediates Lapatinib Resistance in Breast Cancer In primary human breast cancers, investigators observed a positive correlation between KLF4/5 transcript abundance, particularly in the human epidermal growth factor receptor 2-enriched subtype. Furthermore, KLF4/5 protein was rapidly upregulated in human breast cancer cells following treatment with the HER2/epidermal growth factor receptor inhibitor, lapatinib. [Cell Death Dis] Full Article Characterization of Macrophage – Cancer Cell Crosstalk in Estrogen Receptor Positive and Triple-Negative Breast Cancer Scientists performed whole transcriptome sequencing of human monocytes that were co-cultured with estrogen receptor positive or triple-negative breast cancer cell lines and studied the biological responses related to the differential gene activation in both monocytes and cancer cells by pathway analysis. [Sci Rep] Full Article ANGPTL2 Increases Bone Metastasis of Breast Cancer Cells through Enhancing CXCR4 Signaling Researchers show that tumor cell-derived angiopoietin-like protein 2 (ANGPTL2) increases responsiveness of breast cancer cells to CXCL12 by promoting up-regulation of CXCR4 in those cells. [Sci Rep] Full Article FOXA2 Attenuates the Epithelial to Mesenchymal Transition by Regulating the Transcription of E-Cadherin and ZEB2 in Human Breast Cancer Researchers found that forkhead box A2 (FOXA2) prevented the epithelial to mesenchymal transition in human breast cancer. They observed a strong correlation between the expression levels of FOXA2 and the epithelial phenotype. [Cancer Lett] Abstract Pnck Overexpression in HER-2 Gene-Amplified Breast Cancer Causes Trastuzumab Resistance through a Paradoxical PTEN-Mediated Process The frequency of pregnancy up-regulated non-ubiquitous calmodulin kinase (Pnck) expression in HER-2-amplified breast cancer was examined by immunohistochemistry, and the impact of Pnck expression in the presence of HER-2 amplification on cancer cell proliferation, clonogenicity, cell-cycle progression, and Trastuzumab sensitivity was examined in vitro by transfection of cells with Pnck. [Breast Cancer Res Treat] Abstract A Membrane-Type-1 Matrix Metalloproteinase (MT1-MMP) – Discoidin Domain Receptor 1 Axis Regulates Collagen-Induced Apoptosis in Breast Cancer Cells To address the impact of type I collagen on the fate of tumor cells, human breast carcinoma MCF-7 cells were cultured within three-dimensional type I collagen gels (3D COL1). They performed a transcriptomic analysis to decipher the molecular mechanisms regulating 3D COL1-induced apoptosis in human breast cancer cells. [PLoS One] Full Article CLINICAL RESEARCH TBCRC 019: Phase II Trial of Nab-PAC with/without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple Negative Breast Cancer Tigatuzumab (TIG) has strong in vitro/in vivo activity against basal-like breast cancer cells enhanced by chemotherapy agents. This study evaluates activity of TIG and chemotherapy in patients with metastatic triple negative breast cancer. [Clin Cancer Res] Abstract Antiangiogenic Therapy in Recurrent Breast Cancer with Lymphangitic Spread to the Chest Wall: A Randomized Phase II Trial of Bevacizumab with Sequential or Concurrent Oral Vinorelbine and Capecitabine Scientists assessed efficacy of bevacizumab in combination with oral chemotherapy in patients with breast cancer with lymphangitic spread to the chest wall and identified surrogate biomarkers of response to bevacizumab. [Breast] Abstract |